Investors

Recent Releases

July 2, 2025

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis GAITHERSBURG, Md. , July 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.

June 23, 2025

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

GAITHERSBURG, Md. , June 23, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and

June 20, 2025

Emergent BioSolutions Announces Addition to Russell 3000® Index

GAITHERSBURG, Md. , June 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the Company will be added to the broad-market Russell 3000 ® Index , effective after the U.S. market closes on June 27, 2025, as part of the annual reconstitution of the Russell U.S.